141 related articles for article (PubMed ID: 7923313)
21. Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.
Sasaki J; Koga S; Kato K; Takii M; Sakai K; Kawasaki K; Kagimoto M; Doi Y; Takada K; Sakaue A
Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):83-8. PubMed ID: 8458681
[TBL] [Abstract][Full Text] [Related]
22. A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population.
Bavanandan S; Morad Z; Ismail O; Chandran A; Thayaparan T; Singaraveloo M
Med J Malaysia; 2005 Jun; 60(2):158-62. PubMed ID: 16114156
[TBL] [Abstract][Full Text] [Related]
23. Effects of benazepril on insulin resistance and glucose tolerance in uremia.
Wu Z; Bao X
Clin Nephrol; 1998 Aug; 50(2):108-12. PubMed ID: 9725782
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive effects of perindopril treatment in adult spontaneously hypertensive rats.
Lee RM; Lu M; Gillies L; Werstiuk ES
Can J Cardiol; 1997 Sep; 13(9):831-5. PubMed ID: 9343032
[TBL] [Abstract][Full Text] [Related]
25. [Effects of perindopril on hypertension, serum angiotensin-I-converting enzyme activity and urine level of N-acetyl-beta-D-glucosaminidase].
Wang Z; Li Y; Zhou Y
Hunan Yi Ke Da Xue Xue Bao; 1997; 22(3):233-6. PubMed ID: 9868122
[TBL] [Abstract][Full Text] [Related]
26. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension.
Lacourcière Y; Béliveau R; Conter HS; Burgess ED; Lepage S; Pesant Y; Spence JD; Asmar R; Carrière S; Plante GE;
Can J Cardiol; 2004 Jun; 20(8):795-9. PubMed ID: 15229761
[TBL] [Abstract][Full Text] [Related]
27. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril.
Poggi L; Renucci JF; Denolle T
Can J Cardiol; 1994 Nov; 10 Suppl D():21D-24D. PubMed ID: 7954035
[TBL] [Abstract][Full Text] [Related]
28. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group.
Myers MG
Can J Cardiol; 1996 Nov; 12(11):1191-6. PubMed ID: 9191512
[TBL] [Abstract][Full Text] [Related]
29. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension.
Böhlen L; Bienz R; Doser M; Papiri M; Shaw S; Riesen W; Weidmann P
J Cardiovasc Pharmacol; 1996 Jun; 27(6):770-6. PubMed ID: 8761842
[TBL] [Abstract][Full Text] [Related]
30. Urapidil compared with diuretics in the treatment of mild-to-moderate essential hypertensive patients: effects on glucose metabolism, insulin sensitivity, and lipid profile.
De Lima MD; Kohlmann NE; Neves FA; Zanella MT; Ribeiro AB; Kohlmann O
Blood Press Suppl; 1994; 4():53-6. PubMed ID: 7804514
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy.
Bönner G; Lederle RM; Scholze J; Stumpe KO
Arzneimittelforschung; 1993 Aug; 43(8):852-5. PubMed ID: 8216441
[TBL] [Abstract][Full Text] [Related]
32. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension.
Luccioni R; Sever PS; Di Perri T; Redon J; Laurandin I; Brault Y; Chastang C; Guez D
J Hypertens; 1995 Dec; 13(12 Pt 2):1847-51. PubMed ID: 8903665
[TBL] [Abstract][Full Text] [Related]
33. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
[TBL] [Abstract][Full Text] [Related]
34. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
35. [The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment].
Pieniazek W; Franczuk P; Janicki K
Przegl Lek; 2001; 58(5):411-4. PubMed ID: 11603173
[TBL] [Abstract][Full Text] [Related]
36. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
Sourgens H; Schmidt J; Derendorf H
Int J Clin Pharmacol Ther; 2003 Jan; 41(1):22-9. PubMed ID: 12564742
[TBL] [Abstract][Full Text] [Related]
37. [Captopril and hydrochlorothiazide combined in the treatment of mild-to-moderate hypertension. Evaluation of sugar and lipid metabolism in a long-term study].
Malacco E; Magenta M; Noia E; Renesto E; Sartini C; Botta GF
Minerva Med; 1989 Oct; 80(10):1115-8. PubMed ID: 2682377
[TBL] [Abstract][Full Text] [Related]
38. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients.
Bak JF; Gerdes LU; Sørensen NS; Pedersen O
Am J Med; 1992 Apr; 92(4B):69S-72S. PubMed ID: 1580283
[TBL] [Abstract][Full Text] [Related]
39. Antihypertensive and metabolic effects of ketanserin in diabetic patients with mild hypertension.
Beretta-Piccoli C; Salvadé G; Bachmann C; Riesen W; Zuppinger K
J Hum Hypertens; 1988 Aug; 2(2):103-10. PubMed ID: 3072419
[TBL] [Abstract][Full Text] [Related]
40. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension.
Oksa A; Gajdos M; Fedelesová V; Spustová V; Dzúrik R
J Cardiovasc Pharmacol; 1994 Jan; 23(1):79-86. PubMed ID: 7511740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
